Maybe the university thinks that Ozempic is not a well known brand in Denmark so being vague will get more clicks. 0.4% of them get a Ozempic prescription per year vs 1.7% of Americans per year. Seems crazy when "Nearly 1 out of every 5 Danish jobs created last year was at Novo", but it's possible.

Another possibility is that they don't wanna tarnish a brand that saved the country from recession last year. No point picking fights with industry over some observational study that has no predictive power